Optimizing Oral Targeted Therapies for HR+/HER2- Breast Cancer

Oral targeted therapies are increasingly used across early-stage and metastatic HR-positive/HER2-negative breast cancer, but optimal use can be complicated by disease setting, biomarker results, prior therapy, tolerability concerns, and adherence needs. In this podcast, expert faculty discuss current evidence and practical strategies for selecting and sequencing oral targeted therapies, applying biomarker-informed decision-making, monitoring and managing adverse events, and using pharmacist-led approaches to support adherence and long-term treatment persistence.